Recent

% | $
Quotes you view appear here for quick access.

International Business Machines Corporation Message Board

garysnoop1 82 posts  |  Last Activity: 20 hours ago Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Happiness is a phone call to Bernie..

    by garysnoop1 Sep 26, 2016 7:57 PM
    garysnoop1 garysnoop1 20 hours ago Flag

    He was more than up beat, he said things should be materializing very soon with out being specific as usual.More positive than usual thou.

  • I did it..

  • Inner-Knowledge people..(how's that for political correctness )

  • Wonder what that bodes for us if anything..

    Sentiment: Strong Buy

  • I have 3 computers and cant get a decent response on this board from yahoo. It's like it's running at half speed,does any one else have this problem or is it my broken down internet company..

  • Or is this all you got..Sad..,you knock ino but don't leave..humm. Some day wou'll be able to own INO..but NOT at .10 a post..Don't you guys have a union ??

  • Reply to

    Ya gota' read this..

    by garysnoop1 Sep 12, 2016 10:07 AM
    garysnoop1 garysnoop1 Sep 13, 2016 8:57 AM Flag

    Any port in a storm...

  • Reply to

    Ya gota' read this..

    by garysnoop1 Sep 12, 2016 10:07 AM
    garysnoop1 garysnoop1 Sep 12, 2016 4:21 PM Flag

    About time..

  • garysnoop1 by garysnoop1 Sep 12, 2016 10:07 AM Flag

    Sept. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (INO) today announced that its Zika vaccine in development has been named a 2016 Technology Breakthrough by the editors of Popular Mechanics magazine, the leading technology voice in the U.S. with millions of readers.

    Inovio has advanced its DNA-based Zika vaccine into two trials in the U.S., Canada and Puerto Rico. Inovio expects to have results before the end of this year for its U.S. study. In addition, the CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for Inovio’s Zika vaccine and this study’s placebo control design to provide exploratory signals of vaccine efficacy. The company expects to meet with regulators next year to determine the most efficient path forward to develop its Zika vaccine and help mitigate this widespread Zika outbreak that has now expanded into the continental United States.

    In selecting Inovio’s Zika vaccine as a 2016 breakthrough technology the magazine cited: “Inovio Pharmaceuticals, the drug company behind what looks to become the fastest vaccine ever to come to market, may be able to halt such a (Zika) spread before it gets out of control. The company shocked the medical world in June by announcing that its Zika vaccine had already received FDA approval for human clinical trials, just nine months after the race to prevent Zika began. If all goes well, its shot will be available to the public as soon as early 2018.”

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “This award recognizes the Inovio scientists and engineers who have advanced Inovio’s Zika vaccine into two human studies. Inovio was the first to manufacture a Zika vaccine, the first to begin human trials and we expect to have the first human trials data late this year.”

    Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (011000.KS) and academic collaborators from the US and Canada who are also working to advance Inovio’s Ebola and MERS vaccines through clinical development.

    There are no approved vaccines or therapies for Zika virus infection. While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

  • Reply to

    Deleated..what happened to freedom of speach?

    by garysnoop1 Sep 2, 2016 1:59 PM
    garysnoop1 garysnoop1 Sep 4, 2016 9:32 AM Flag

    Yascrew wouldn't post it here ,so I did the news on the new board..Yadumb is a really screwed up outfit..

  • go to the new... board

  • Reply to

    GeneOne..

    by garysnoop1 Aug 31, 2016 4:24 PM
    garysnoop1 garysnoop1 Sep 1, 2016 12:26 PM Flag

    For the ones that dont get it,..

  • PLYMOUTH MEETING, Pa. – August 29, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

    Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (KSE: 011000) and academic collaborators from the US and Canada who are also working to advance Inovio’s Ebola and MERS vaccines through clinical development.

    In June, Inovio was the first to commence a human Zika trial, with sites in the U.S. and Canada. All 40 subjects for the first clinical study have been fully enrolled and dosed. Inovio expects to report results before the end of this year.

    There are no approved vaccines or therapies for Zika virus infection. While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

    Inovio’s second clinical study is a placebo-controlled, double-blind trial involving 160 healthy adult volunteers (80 subjects will receive vaccine and 80 subjects will receive placebo) to evaluate the safety, tolerability and immunogenicity of GLS-5700 administered with Inovio’s CELLECTRA®-3P device. This proprietary intradermal DNA vaccine delivery device has been shown to maximize antigen expression and immune responses in multiple human studies. Inovio will also assess differences in Zika infection rates in participants given either placebo or vaccine as part of an exploratory endpoint. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.

  • PLYMOUTH MEETING, Pa. – August 29, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

    Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (KSE: 011000) and academic collaborators from the US and Canada who are also working to advance Inovio’s Ebola and MERS vaccines through clinical development.

    In June, Inovio was the first to commence a human Zika trial, with sites in the U.S. and Canada. All 40 subjects for the first clinical study have been fully enrolled and dosed. Inovio expects to report results before the end of this year.

    There are no approved vaccines or therapies for Zika virus infection. While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

    Inovio’s second clinical study is a placebo-controlled, double-blind trial involving 160 healthy adult volunteers (80 subjects will receive vaccine and 80 subjects will receive placebo) to evaluate the safety, tolerability and immunogenicity of GLS-5700 administered with Inovio’s CELLECTRA®-3P device. This proprietary intradermal DNA vaccine delivery device has been shown to maximize antigen expression and immune responses in multiple human studies. Inovio will also assess differences in Zika infection rates in participants given either placebo or vaccine as part of an exploratory endpoint. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.

  • garysnoop1 by garysnoop1 Aug 31, 2016 4:24 PM Flag

    About GeneOne Life Science

    GeneOne Life Science, Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for preclinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. VGXI manufactured the Zika vaccine and other emerging disease vaccines including Ebola and MERS

  • Reply to

    Where are the Inovio news?

    by bballgm Aug 31, 2016 2:05 PM
    garysnoop1 garysnoop1 Aug 31, 2016 3:17 PM Flag

    I hope the low hanging fruit isn't makes wine,not vinigar !!

  • The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.
    In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.
    Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s

  • garysnoop1 by garysnoop1 Aug 29, 2016 11:22 AM Flag

    Inovio Pharmaceuticals, Inc. (Nasdaq: INO) announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

  • Inovio completed end-of-Phase 2 meetings with both the FDA and European Medicines Agency (EMA) back in April, with both agencies discussing the development plan of the firm’s pipeline drug, VGX-3100, a therapeutic synthetic DNA vaccine treatment targeting cervical dysplasia caused by the human papillomavirus (HPV). Aschoff finds Inovio “on track” to initiate a Phase 3 trial in its fourth quarter following affirmative opinions from the FDA and EMA on the pipeline.

    INO’s commercial design for the intramuscular immunotherapy delivery to be administered for the Phase 3 trial has been finalized, with the firm to reveal the official design plans at initiation. Aschoff notes that Inovio’s fourth quarter will include several clinical read-outs that will prove significant, from its multi-center Phase 1 Zika virus vaccine (GLS-5700) trial, designed to treat the major ongoing epidemic in North and South America causing devastating birth defects. Interim immune response and safety data for the vaccine will be forthcoming. Additionally due for fourth-quarter are results for INO-3112, in Phase 1 to test HPV immunotherapy in head and neck cancer.

    The analyst notes, “Inovio and GeneOne Life Science completed enrollment of 75 healthy volunteers in the Phase 1 trial of their GLS-5300 MERS vaccine, with interim data expected in 4Q16. Interim results are also expected in 4Q16 from the Phase 1 trial of INO-5150 for prostate cancer targeting PSMA and PSA, now fully enrolled. Inovio ended 2Q16 with $134.5 million in cash, which should be sufficient to support its operations into 2018, including the $80 million in costs associated with the Phase 3 trial of VGX-3100.”

    Overall, Aschoff remains bullish on Inovio’s clinical progress. Looking into the next quarter, the analyst believes, “We expect Inovio to combine this newly acquired technology with its current electroporation devices and optimize its delivery device in the long run.”

IBM
158.11-0.18(-0.11%)Sep 29 4:01 PMEDT